Education
About Us
Working with TipRanks
Follow Us
Niagen Bioscience (NAGE)
NASDAQ:NAGE
NAGE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.31 - $9.18
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.41M
Market Cap
$477.39M
Enterprise ValueN/A
Total Cash (Recent Filing)$538.67K
Total Debt (Recent Filing)$328.77K
Price to Earnings (P/E)58.3
Beta0.78
Next Earnings
May 07, 2025EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding77,750,450
10 Day Avg. Volume793,847
30 Day Avg. Volume1,411,114
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.05
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$9.03Price Target Upside47.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsKey clinical study in Parkinson's disease is expected to yield results, with previous studies showing NR therapy to be well tolerated and associated with clinical improvement.
International SalesA significant portion of the company's revenue comes from international sales unaffected by recent trade policy changes, including a key revenue stream from a duty-free market in Hong Kong.
Revenue GrowthChromaDex reported $25.6M in top-line revenue, modestly ahead of the forecast for $25M.
Bears Say
Regulatory ChallengesIf the NO-PARK results prove positive, Niagen Bioscience is expected to explore the possibility of obtaining regulatory approval for a pharmaceutical-grade formulation of NR to treat Parkinson's disease, possibly through a spinout company or joint venture with a pharmaceutical company as partner.
Sales And Marketing ExpensesSales and marketing expenses accounted for only 27.5% of net sales vs. 31% in the year-ago period.
---
Ownership Overview
29.85%
Insiders
6.99%
Mutual Funds
7.48% Other Institutional Investors
48.78% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NAGE FAQ
What was Niagen Bioscience’s price range in the past 12 months?
Niagen Bioscience lowest stock price was $2.31 and its highest was $9.18 in the past 12 months.
What is Niagen Bioscience’s market cap?
Niagen Bioscience’s market cap is $477.39M.
When is Niagen Bioscience’s upcoming earnings report date?
Niagen Bioscience’s upcoming earnings report date is May 07, 2025 which is in 21 days.
How were Niagen Bioscience’s earnings last quarter?
Niagen Bioscience released its earnings results on Mar 04, 2025. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.022 by $0.068.
Is Niagen Bioscience overvalued?
According to Wall Street analysts Niagen Bioscience’s price is currently Undervalued.
Does Niagen Bioscience pay dividends?
Niagen Bioscience does not currently pay dividends.
What is Niagen Bioscience’s EPS estimate?
Niagen Bioscience’s EPS estimate is 0.02.
How many shares outstanding does Niagen Bioscience have?
Niagen Bioscience has 77,750,450 shares outstanding.
What happened to Niagen Bioscience’s price movement after its last earnings report?
Niagen Bioscience reported an EPS of $0.09 in its last earnings report, beating expectations of $0.022. Following the earnings report the stock price went up 52.679%.
Which hedge fund is a major shareholder of Niagen Bioscience?
Currently, no hedge funds are holding shares in NAGE
---
Niagen Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.03 (47.07% Upside)
$9.03 (47.07% Upside)
Blogger Sentiment
Bullish
NAGE Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 26.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
59.48%
12-Months-Change
Fundamentals
Return on Equity
22.94%
Trailing 12-Months
Asset Growth
24.22%
Trailing 12-Months
Company Description
Niagen Bioscience
Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.
---
NAGE Company Deck
---
NAGE Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial performance with record revenues, increased cash flow, and improved operational efficiency. However, the company faces challenges in the supply chain and regulatory landscape, necessitating vigilance against market competitors' misleading practices. Overall, the positive financial results and strategic initiatives suggest a promising outlook despite these challenges.Read More>---
NAGE Stock 12 Month Forecast
Average Price Target
$9.03
▲(47.07% Upside)
Technical Analysis
Sinovac Biotech
―
Bicycle Therapeutics
―
Opthea Limited Sponsored ADR
―
Maravai Lifesciences Holdings
―
Sana Biotechnology
―
Best Analysts Covering NAGE
1 Year
1 Year Success Rate
7/12 ratings generated profit
1 Year Average Return
+60.36%
reiterated a buy rating 9 days ago
Copying Sean McGowan's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +60.36% per trade.
---